Abelacimab: New Anticoagulant Prevents Blood Clots with Near-Zero Bleeding Risk in Phase 3 Trial

How Does Abelacimab Prevent Clots Without Causing Bleeding?

All currently available anticoagulants — warfarin, heparin, DOACs (rivaroxaban, apixaban, edoxaban) — work by inhibiting coagulation factors (primarily thrombin or factor Xa) that are essential for both pathological clotting AND normal hemostasis (wound healing). This is why bleeding is an inevitable side effect: every patient on blood thinners has increased risk of bruising, gastrointestinal bleeding, and intracranial hemorrhage.

Factor XI occupies a unique position in the coagulation cascade. Research has shown that it amplifies and sustains pathological thrombus formation (the type that causes strokes and deep vein thrombosis) but contributes minimally to the initial hemostatic plug that stops bleeding from wounds. People born with factor XI deficiency — studied extensively in Israeli populations — have very low rates of spontaneous thrombosis and generally mild bleeding tendencies, mostly limited to surgical sites. Abelacimab exploits this biology by specifically blocking factor XI with a monoclonal antibody, achieving anticoagulation without meaningfully impairing wound healing.

What Were the Key Clinical Trial Results?

The AZALEA-TIMI 71 trial randomized 1,287 patients with non-valvular atrial fibrillation at 95 centers across 7 countries to one of three arms: abelacimab 150mg subcutaneous injection monthly, abelacimab 90mg monthly, or rivaroxaban 20mg daily. The trial was stopped early by the independent data safety monitoring board (DSMB) due to overwhelming evidence of bleeding reduction with abelacimab.

For bleeding outcomes, abelacimab 150mg showed a rate of major or clinically relevant non-major bleeding of approximately 3.2 per 100 person-years compared to 8.4 per 100 person-years with rivaroxaban — a roughly 62% relative reduction. For major bleeding alone, the reduction was approximately 74%. Stroke prevention efficacy appeared comparable between the groups, though the early termination of the trial limited the statistical power for definitive efficacy conclusions. These results were published in the New England Journal of Medicine in 2025.

Who Would Benefit Most from Abelacimab?

An estimated 30–40% of atrial fibrillation patients who would benefit from anticoagulation either do not receive it or discontinue it due to bleeding concerns. This treatment gap is particularly pronounced in elderly patients (over 80), those with prior gastrointestinal hemorrhage, patients on concurrent antiplatelet therapy (after stent placement), and individuals with chronic kidney disease (which increases both clotting and bleeding risk).

The AZALEA-TIMI 71 results suggest that abelacimab's bleeding advantage may be maintained across high-risk populations, though confirmatory Phase 3 data is needed. The monthly injection format also offers adherence advantages for patients who struggle with daily oral medication — anticoagulant non-adherence is estimated at 30–50% within the first year and is a major cause of breakthrough strokes. Phase 3 trials, including LILAC-TIMI 76 (studying AF patients deemed unsuitable for standard anticoagulation), are now underway to confirm these benefits in the populations that stand to gain the most.

When Will Abelacimab Be Available?

Novartis acquired Anthos Therapeutics in early 2025 for up to $3.1 billion, signaling strong confidence in abelacimab's potential. The FDA has granted Fast Track Designation for abelacimab in both atrial fibrillation and cancer-associated thrombosis, which allows for expedited regulatory interactions. Multiple Phase 3 trials are underway: LILAC-TIMI 76 for AF patients unsuitable for current anticoagulants, ASTER for cancer-associated VTE versus apixaban, and MAGNOLIA for GI/GU cancer-associated VTE versus dalteparin.

Several other factor XI/XIa inhibitors are also in development. Milvexian (Bristol Myers Squibb/Janssen) and asundexian (Bayer) are oral factor XIa inhibitors in Phase 3 testing, though asundexian's OCEANIC-AF trial was stopped for inferiority to apixaban in AF. The competition in this space underscores both the scientific promise and the challenges of translating the factor XI hypothesis into approved therapies. If abelacimab's Phase 3 trials succeed, it could become the first approved drug in this entirely new anticoagulant class.